Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay

Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay
Targeted FLNc S2233 S2236 phosphorylation assay
  • Organism: Homo sapiens, Mus musculus
  • Instrument: Q Exactive Plus
  • SpikeIn: Yes
  • Keywords: FLNc, phosphoproteomics, PRM assay
  • Submitter: Lena Reimann
Abstract
In FLNc 10 phosphosites in FLNc (including S2234, S2237 and T2239) were found to be differentially phosphorylated. FLNc-pS2234 was by far the most abundant phosphosite followed by pS2237, while levels of FLNc-pT2239 were very low. pS2234 and pS2237 are part of the extended basophilic motif which is located in Ig-like domain 20 (d20)of FLNc. While levels of pS2234 and pS2234/pS2237 were strongly reduced following inhibition of PI3K/Akt signaling and increased upon IGF1-mediated stimulation, the levels were reversed for pS2237. This suggests that concurrent phosphorylation of FLNc at S2234 and S2237 prevails in vivo with pS2234 being the main site regulated by PI3K/Akt. In vitro kinase assays coupled to LC-MS (n=4) confirmed hFLNC-S2233 as prominent substrate site of Akt, while PKC alpha preferentially phosphorylateds S2236 in vitro. Accordingly, incubation with both kinases led to an increase of the doubly phosphorylated (pS2233 and pS2236) form. To validate these findings in myocytes, we performed an in cellulo kinase assays with pharmacologic interventions using Gö6976, PMA, IGF.1 and MK-2206, respectively, or a combination of the two inhibitors with PMA and IGF-1 followed by targeted MS analysis.
Experiment Description
Mouse C2 cells transiently expressing BirA* FLNc d18-21 were treated for 1 h with 10 µM MK-2206 (Selleck) or 10 µM Gö6976 (Merck) for 1 h or with 300 nM PMA (Sigma Aldrich) or IGF-1 (sigma Aldrich) for 15 min. In experiments using both, inhibitor and activator, cells were first treated with the respective inhibitor (MK-2206, Gö6976) for 1 h and PMA or IF-1 was added for the last 15 min of the treatment. Cells were lysed on ice with 500 µl modified RIPA buffer. Enrichment of the Myc-tagged FLNc fragment was performed with 10 µl Myc-Dynabeads (Invitrogen) according to the manufacturer’s protocol. On-bead tryptic digestion was performed in 200 µl ammonium bicarbonate solution (50 mM) for 3.5 h at 42°C and 1,400 rpm on a thermoshaker using sequencing grade trypsin,(Promega) in a 1:50 (w/w) ratio. Phosphopeptides were enriched as described above and mixed with 47.5-95 fmol phosphopeptides of a phosphopeptide standard comprising 181 phosphopeptides (Intavis). For targeted MS analysis on a QExactive Plus instrument, an inclusion list comprising 40 different precursor masses was generated with Skyline 2.6.0.6709. One scan cycle consisted of a full MS1 scan at a resolution of 70,000, an automatic gain control (AGC) target of 3e6 ions, a max. ion time of 20 ms and a scan range from m/z 400 to 1600, followed by 10 PRM scans. Each PRM scan targeted one precursor of the inclusion list at a resolving power of 17,500, an AGC target of 2e5, a max. ion time of 49 ms and an isolation window of 2 m/z. Raw files were analyzed with Skyline and intensities of hFLNc phosphopeptides were normalized to the summed intensities of eight phosphopeptides (SEGpSPVLPHEPAK, TGMGSGpSAGKEGGPFK, pSTVASMMHR, VIEDNEpYTAR, LIEDNEpYTAR, pSFNGSLKNVAVDELSR, pSGGQRHSPLSQR, AYpTHQVVTR) from the standard under control conditions.
Created on 3/4/20, 1:17 PM
Clustergrammer Heatmap
 
Download
SPE_recovery_part 2.sky.zip2025-09-11 14:19:0522459026612
SPE recovery_part 1_A1AT, A1AG, IgA.sky.zip2025-09-11 14:19:05611226612
Intra- and interday precision_part 2.sky.zip2025-09-11 14:19:0222459027418
Intra- and interday precision_part 1_ A1AT, A1AG, IgA.sky.zip2025-09-11 14:19:02611226718
Proteomic analysis of 98 UCP samples.sky.zip2025-09-11 14:18:46285611234098
Proteomic analysis of 98 MP samples.sky.zip2025-09-11 14:18:46285611234098
Calibration_part 2.sky.zip2025-09-11 14:18:4122454914445
Calibration_part 1_A1AT, A1AG, IgA.sky.zip2025-09-11 14:18:39611226448
Standard_Add_2025-09-11_13-43-33.sky.zip2025-09-11 13:43:472361825
Val_Stability_2025-09-11_13-42-55.sky.zip2025-09-11 13:43:0223618240
Val_Interference_2025-09-11_13-41-27.sky.zip2025-09-11 13:41:332361845
ProINS_Imprecision_2025-09-11_13-40-32.sky.zip2025-09-11 13:40:402361898
AbLotComparison_2025-09-11_13-39-42.sky.zip2025-09-11 13:39:493282416
Buffers_Ab_2025-09-11_13-38-31.sky.zip2025-09-11 13:38:371363522
IAA_peptides_2025-09-11_13-36-33.sky.zip2025-09-11 13:36:4243123879
Buffers_digest_2025-09-11_13-13-51.sky.zip2025-09-11 13:13:581363522
PFAS and Autoimmune Disease Skyline Document - NTA and SSA_2025-09-02_11-27-20.sky.zip2025-09-02 15:17:57602929203
PFAS and Autoimmune Disease Skyline Document - Absolute Quant_2025-09-02_11-26-32.sky.zip2025-09-02 15:17:57505353286
TPAD_totalCSF-multiNF-DIANN_Batch8_annotated.sky.zip2025-08-28 12:23:582,50424,98830,183239,58254
humanMVs_expt3_pepsInAll3_2025-07-21_15-21-49.sky.zip2025-08-14 00:10:264,33830,60130,601211,47929
humanMVs_expt2_pepsInAll3_2025-07-21_15-14-15.sky.zip2025-08-14 00:10:264,33830,60130,601211,52421
humanMVs_expt1_pepsInAll3_2025-07-21_15-01-07.sky.zip2025-08-14 00:10:264,33830,60130,601209,46334
humanMVs_expt3_2025-07-21_14-42-08.sky.zip2025-08-14 00:10:266,07565,24665,246444,45729
humanMVs_expt2_2025-07-21_12-54-40.sky.zip2025-08-14 00:10:266,19360,86260,862421,24621
humanMVs_expt1_2025-07-21_12-28-41.sky.zip2025-08-14 00:10:265,76359,38259,382409,06134
METRIC_Eclipse_PSB_All_QCs_2025-08-08_23-10-58.sky.zip2025-08-08 20:11:061666237
Kang_et_al_Proteomics_FigS3_2025-08-06_12-31-18.sky.zip2025-08-07 17:30:53618187130
ecoli_large_replicates_loaded_refined_2024-05-30_14-02-04.sky.zip2025-08-05 20:49:443669899894,9408
ecoli_large_replicates_loaded_2024-05-30_14-00-59.sky.zip2025-08-05 20:49:444611,3021,3027,5248
ecoli_large_replicates_2024-05-30_14-00-05.sky.zip2025-08-05 20:49:444611,3021,3027,5240
ecoli_subset_replicates_refined_cv_2024-05-30_13-58-18.sky.zip2025-08-05 20:49:447592,2662,26612,8072
ecoli_subset_replicates_refined_2024-05-30_13-57-25.sky.zip2025-08-05 20:49:447592,4372,43713,6022
ecoli_subset_replicates_2024-05-30_13-56-16.sky.zip2025-08-05 20:49:447592,4372,44130,8572
gpf_results_importer_2024-05-30_13-54-14.sky.zip2025-08-05 20:49:441,1925,3967,42785,6731
gpf_results_manual_2024-05-30_13-52-23.sky.zip2025-08-05 20:49:441,1925,3967,42785,6731
pq500_100spd_plasma_final_lightheavy_replicates_2024-05-30_13-50-10.sky.zip2025-08-05 20:48:155798181,62213,69910
pq500_60spd_plasma_final_lightheavy_replicates_2024-05-30_13-48-26.sky.zip2025-08-05 20:48:155798181,62213,87610
pq500_100spd_plasma_final_replicates_2024-05-30_13-47-38.sky.zip2025-08-05 20:48:155798188187,08110
pq500_60spd_plasma_final_replicates_2024-05-30_13-46-43.sky.zip2025-08-05 20:48:155798188186,97710
pq500_100spd_plasma_multireplicate_results_refined_2024-05-30_13-46-07.sky.zip2025-08-05 20:48:155798188187,0811
pq500_60spd_plasma_multireplicate_results_refined_2024-05-30_13-45-40.sky.zip2025-08-05 20:48:155798188186,9771
pq500_100spd_plasma_multireplicate_results_2024-05-30_13-45-07.sky.zip2025-08-05 20:48:155798188187,6512
pq500_60spd_plasma_multireplicate_results_2024-05-30_13-44-21.sky.zip2025-08-05 20:48:155798188187,6012
pq500_100spd_neat_multireplicate_results_refined_2024-05-30_13-43-42.sky.zip2025-08-05 20:48:155798188187,6891
pq500_60spd_neat_multireplicate_results_refined_2024-05-30_13-43-05.sky.zip2025-08-05 20:48:155798188187,6011
pq500_100spd_neat_multireplicate_results_2024-05-30_13-42-26.sky.zip2025-08-05 20:48:1557981881811,0881
pq500_60spd_neat_multireplicate_results_2024-05-30_13-41-26.sky.zip2025-08-05 20:48:1557981881811,0881
pq500_60spd_neat_multireplicate_2024-05-30_13-40-53.sky.zip2025-08-05 20:48:1557981881811,0880
Crossfeeding_PlateD.sky.zip2025-07-31 18:21:50501212247
Crossfeeding_PlateC.sky.zip2025-07-31 18:21:50501212247
Crossfeeding_PlateB.sky.zip2025-07-31 18:21:50501212247
Crossfeeding_PlateA.sky.zip2025-07-31 18:21:50501212247
Monoculture_Verruco25.sky.zip2025-07-31 18:21:50501212178
Monoculture_Flavo40.sky.zip2025-07-31 18:21:50501212162
Monoculture_Flavo56.sky.zip2025-07-31 18:21:49501212138
Monoculture_Verruco69.sky.zip2025-07-31 18:21:49501212204
Monoculture_Gamma88.sky.zip2025-07-31 18:21:49501212134
Monoculture_Flavo94.sky.zip2025-07-31 18:21:49501212146
Monoculture_Verruco4.sky.zip2025-07-31 18:21:49501212180
Monoculture_Flavo12.sky.zip2025-07-31 18:21:49501212190
PairwiseCoCultures_Verruco4.sky.zip2025-07-31 18:21:49501212247
PairwiseCoCultures_Verruco69.sky.zip2025-07-31 18:21:49501212247
PairwiseCoCultures_Verruco25.sky.zip2025-07-31 18:21:49501212247
Monoculture_AllStrains.sky.zip2025-07-31 18:21:49501212247
FucoidanDiversity_PlateF.sky.zip2025-07-31 18:21:49501212247
FucoidanDiversity_PlateE.sky.zip2025-07-31 18:21:49803434150
FucoidanDiversity_PlateD.sky.zip2025-07-31 18:21:49501212151
FucoidanDiversity_PlateC.sky.zip2025-07-31 18:21:49803434102
FucoidanDiversity_PlateB.sky.zip2025-07-31 18:21:49501212199
FucoidanDiversity_PlateA.sky.zip2025-07-31 18:21:49803434126
7DegraderCommunity_PlateD.sky.zip2025-07-31 18:21:49501212247
7DegraderCommunity_PlateC.sky.zip2025-07-31 18:21:49501212247
7DegraderCommunity_PlateA.sky.zip2025-07-31 18:21:49501212247
7DegraderCommunity_PlateB.sky.zip2025-07-31 18:21:49501212247
hela_2025-07-21_15-14-01.sky.zip2025-07-23 10:27:101,8379,1829,64986,7361
mouse_2025-07-21_15-13-32.sky.zip2025-07-23 10:27:101,4147,6538,39875,5071
yeast_2025-07-21_15-12-08.sky.zip2025-07-23 10:27:101756016525,8661
DSS Response curve_105plex_5repeats_2025-07-11_01-47-02.sky.zip2025-07-14 10:02:329610522063860
210723-ATI-barley-Pt14_2025-02-24_01-08-00.sky.zip2025-07-02 20:45:211010198733
210423-ATI-barley-Pt13_2025-02-24_01-07-11.sky.zip2025-07-02 20:45:201010194027
210416-ATI-barley-Pt12_2025-02-24_01-06-33.sky.zip2025-07-02 20:45:181010193843
210415-ATI-barley-Pt11_2025-02-24_01-05-41.sky.zip2025-07-02 20:45:161010194029
210302-ATI-barley-Pt10_2025-02-24_01-05-05.sky.zip2025-07-02 20:45:151010194234
210224-ATI-barley-Pt9_2025-02-24_01-04-22.sky.zip2025-07-02 20:45:131010194031
210217-ATI-barley-Pt8_2025-02-24_01-03-46.sky.zip2025-07-02 20:45:121010194029
210210-ATI-barley-Pt7_2025-02-24_01-03-02.sky.zip2025-07-02 20:45:101010194631
210203-ATI-barley-Pt6_2025-02-24_01-02-20.sky.zip2025-07-02 20:45:091010195031
210129-ATI-barley-Pt5_2025-02-24_01-01-22.sky.zip2025-07-02 20:45:071010195831
200731-ATI-barley-Pt4_2025-02-24_01-00-26.sky.zip2025-07-02 20:45:061010198719
200717-ATI-barley-Pt3_2025-02-24_00-58-01.sky.zip2025-07-02 20:45:041010198755
200709-ATI-barley-Pt2-Response_2025-02-24_00-56-48.sky.zip2025-07-02 20:45:01101019957
200709-ATI-barley-Pt2_2025-02-24_00-55-11.sky.zip2025-07-02 20:45:011010199136
200602-ATI-barley-Pt1_2025-02-24_00-25-35.sky.zip2025-07-02 20:44:591010199331
TPAD_CSF1A_Batch1-multiNF-DIANN.sky.zip2025-07-01 17:49:472,85327,12832,575259,53243
TPAD_CSF1A_Batch1-multiNF-DIANN-grouped.sky.zip2025-07-01 17:41:312,67226,43931,769253,11943
TPAD_CSF1B_Batch2-multiNF-DIANN.sky.zip2025-07-01 15:26:132,85327,12832,575259,53241
TPAD_CSF1B_Batch2-multiNF-DIANN-grouped.sky.zip2025-07-01 15:17:422,67226,43931,769253,11941
TPAD_CSF2A_Batch3-multiNF-DIANN.sky.zip2025-07-01 14:13:302,85327,12832,575259,53243
TPAD_CSF2A_Batch3-multiNF-DIANN-grouped.sky.zip2025-07-01 14:04:582,67226,43931,769253,11943
TPAD_CSF2B_Batch4-multiNF-DIANN.sky.zip2025-07-01 11:21:372,85327,12832,575259,53243

 

Fig4C.

Cell-based kinase assay. PKC activator PMA, PKCa inhibitor Gö6976 and Akt activator IGF-1 and inhibitor MK-2206 were used to activate or block signaling pathways in C2 cells. For targeted MS analysis, phosphopeptides were enriched by Myc-tag and TiO2-based enrichment.

Figure 4D.

Immunoblot analysis of PKCα and Akt activities in C2 cells following pharmacologic interventions as indicated in 4C. Pan- and phospho-specific antibodies were used to detect total protein amounts and phosphoisoforms. GAPDH was used as loading control.

Figure 4e.

Targeted MS data of hFLNc phosphopeptides comprising the phosphorylation sites pS2233, pS2233/pS2236 and pS2236. MS data were quantified using Skyline and normalized to an internal phosphopeptide standard and the mock-treated control (DMSO). Intensities of phosphopeptides distinctive for a specific phosphorylation site in hFLNc d18-21 WT were added up per experiment and represented as normalized mean log2 ratio (treatment/control) ± SEM (n=4; *, p ≤ 0.05; **, p ≤ 0.01)

 

This data is available under the CC BY 4.0 license.